# A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.

> **NCT06142617** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 37 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- Immune Checkpoint Inhibitor
- EGFR Exon 21 Mutation

## Interventions

- **DRUG:** Pembrolizumab, pemetrexed, platinum
- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT06142617
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-12-01
- **Primary completion:** 2027-11-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2023-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06142617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06142617, "A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06142617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*